Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide capsules - AstraZeneca

Drug Profile

Budesonide capsules - AstraZeneca

Alternative Names: Budecol; Budesonide CIR capsule; Budesonide Controlled Ilieal Release capsule; D9421-C; Entocir; Entocord; Entocort; Zentacort

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Tillotts Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Microscopic colitis; Proctitis; Ulcerative colitis

Most Recent Events

  • 23 Feb 2018 Launched for Microscopic colitis in United Kingdom (PO)
  • 05 Feb 2018 Registered for Microscopic colitis in United Kingdom (PO) before February 2018
  • 29 Nov 2016 Launched for Crohn's disease in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top